Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01665508 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT01665508: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01665508 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01665508, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
Women have less significant blockages of coronary arteries, however have greater symptoms and worse outcomes compared to their age-matched male counterparts. This paradox has led to the recognition and importance of the microvasculature ( small vessels) as a contributor to symptoms and outcomes. Nebivolol has unique antioxidant properties and dilates blood vessels and it is therefore proposed that treatment with nebivolol will reduce angina (chest symptoms) in women with microvascular disease as well as improve exercise capacity, reduce resource utilization and improve other measures of artery function.
Interventions
- DRUG Nebivolol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01665508
The ClinicalTrials.gov registry entry for NCT01665508 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.
NCT01665508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01665508 about?
NCT01665508 is a clinical study titled "Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease". Women have less significant blockages of coronary arteries, however have greater symptoms and worse outcomes compared to their age-matched male counterparts. This paradox has led to the recognition and importance of the microvasculature ( small vessels) as a contributor to symptoms and outcomes. Neb...
What is the current status of trial NCT01665508?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2013-04. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01665508?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT01665508?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.